

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 June 2018 (28.06.2018)



(10) International Publication Number
WO 2018/115960 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) **A61P 35/00** (2006.01)
A61K 39/395 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2017/001677

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:
18 December 2017 (18.12.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
16382617.5 19 December 2016 (19.12.2016) EP
62/467,017 03 March 2017 (03.03.2017) US
17382683.5 13 October 2017 (13.10.2017) EP

(71) Applicants: **MOSAIC BIOMEDICALS, S.L.** [ES/ES];
Passeig Vall D'hebron, 119, Edificio Mediterranea, 08035
Barcelona (ES). **FUNDACIO PRIVADA INSTITUCIO**
CATALANA DE RECERCA I ESTUDIS AVAN-
CATS [ES/ES]; Passeig Lluís Companys, 23, 08010
Barcelona (ES). **FUNDACIO PRIVADA INSTITUT**
D'INVESTIGACIO ONCOLOGICA DE VALL HE-
BRON [ES/ES]; Natzaret, 115-117, Edifici Cellex, 08035
Barcelona (ES).

(72) Inventors: **SUAREZ, Joan, Seoane**; Carrer Natzaret
115-117, Edifici Cellex, 08035 Barcelona (ES).
FOLGUEIRA, Judit, Anido; Carrer Natzaret 115-117,
Edifici Cellex, 08035 Barcelona (ES). **FRANSSON, Jo-**
han; 101 College Street, Tmdt 11-301, Toronto, Ontario,
M5G 1L7 (CA). **JULIEN, Jean-philippe**; 30 Firstbrooke
Road, Toron, Ontario, M4E 2L1 (CA). **RAMAN, Swetha**;
20 Carlton Street, Apt. 1028, Toronto, Ontario, M5B 2H5
(CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTIBODIES AGAINST LIF AND USES THEREOF

(57) Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.



WO 2018/115960 A1